AKT and MET signalling mediates antiapoptotic radioresistance in head neck cancer cell lines

Oral Oncology

Volumn 51, Issue 2, 2015, Pages 158-163

  Ettl, Tobias ^a   Viale Bouroncle, Sandra ^a   Hautmann, Matthias G ^a   Gosau, Martin ^a   Kölbl, Oliver ^a   Reichert, Torsten E ^a   Morsczeck, Christian ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

AKT; ALDH; Apoptosis; Head neck cancer; Irradiation; MET; Stem cells

Indexed keywords

BCL2 RELATED PROTEIN A1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IRRADIATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; CANCER STEM CELL; ENZYMOLOGY; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; RADIATION TOLERANCE; SIGNAL TRANSDUCTION;

EID: 84922641414     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2014.11.005     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008;371:1695-709.
3. Nguyen LN, Ang KK. Radiotherapy for cancer of the head and neck: altered fractionation regimens. Lancet Oncol 2002;3:693-701.
4. Nguyen NP, Vock J, Chi A, Vinh-Hung V, Dutta S, Ewell L, et al. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2012;188:677-83.
5. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol: J Int Soc Oncodev Biol Med 2010;31:363-72.
6. Li J-Y, Li Y-Y, Jin W, Yang Q, Shao Z-M, Tian X-S. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res 2012;31:102.
7. An J, Chervin AS, Nie A, Ducoff HS, Huang Z. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene 2007;26:652-61.
8. Khan Z, Khan N, Tiwari RP, Patro IK, Prasad GBKS, Bisen PS. Down-regulation of survivin by oxaliplatin diminishes radioresistance of head and neck squamous carcinoma cells. Radiother Oncol 2010;96:267-73.
9. Li JY, Li YY, Jin W, Yang Q, Shao ZM, Tian XS. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res: CR 2012;31:102.
10. Krause M, Yaromina A, Eicheler W, Koch U, Baumann M. Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin Cancer Res 2011;17:7224-9.
11. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9:288-96.
12. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
13. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
14. Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: radiation therapy oncology group RTOG- 0234. J Clin Oncol: Off J Am Soc Clin Oncol 2014;32:2486-95.
15. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: eastern cooperative oncology group trial E3303. Clin Cancer Res 2014;20:5041-51.
16. Bhardwaj V, Cascone T, Cortez MA, Amini A, Evans J, Komaki RU, et al. Modulation of c-Met signaling and cellular sensitivity to radiation. Cancer 2013;119:1768-75.
17. Baschnagel AM, Williams L, Hanna A, Chen PY, Krauss DJ, Pruetz BL, et al. CMet expression is a marker of poor prognosis in patients with locally advanced head and neck squamous cell carcinoma treated with chemoradiation. Int J Radiat Oncol Biol Phys 2014;88:701-7.
18. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.
19. Lim YC, Kang HJ, Moon JH. C-Met pathway promotes self-renewal and tumorigenecity of head and neck squamous cell carcinoma stem-like cell. Oral Oncol 2014;50:633-9.
20. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, et al. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 1989;49:5167-75.
21. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: relevance to radiotherapy. Int J Radiat Oncol Biol Phys 1995:781-96.
22. Lei Y, Geng Z, Guo-Jun W, He W, Jian-Lin Y. Prognostic significance of survivin expression in renal cell cancer and its correlation with radioresistance. Mol Cell Biochem 2010;344:23-31.
23. Capalbo G, Rodel C, Stauber RH, Knauer SK, Bache M, Kappler M, et al. The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al.] 2007;183:593-9.
24. Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008;14:6496-504.
25. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005:635-45.
26. Jeong S-Y. c-Myc down-regulation is involved in proteasome inhibitormediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer. Int J Oncol 2012;40:385-90.
27. Hoffman B, Liebermann DA. The proto-oncogene c-myc and apoptosis. Oncogene 1998;17:3351-7.
28. Qiu W, Schönleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006:1441-6.
29. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003;22:8983-98.
30. Szumiel I. Epidermal growth factor receptor and DNA double strand break repair: the cell's self-defence. Cell Signal 2006:1537-48.
31. Toulany M, Dittmann K, Krüger M, Baumann M, Rodemann HP. Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. Radiother Oncol 2005:143-50.
32. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
33. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Sol Degese M, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. J Natl Cancer Inst 2014;106.
34. Li P, Zhang Q, Torossian A, Li ZB, Xu WC, Lu B, et al. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer. Int J Radiat Oncol Biol Phys 2012;83:e391-7.
35. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999;96:4240-5.
36. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 2000;20:5010-8.
37. Yang Z, Yuan X-G, Chen J, Luo S-W, Luo Z-J, Lu N-H. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin Res Hepatol Gastroenterol 2013;37:72-9.
38. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26.
39. Bacco Fd, Luraghi P, Medico E, Reato G, Girolami F, Perera T, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. JNCI J Natl Cancer Inst 2011;103:645-61.
40. Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy A, et al. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998;17:131-41.
41. Sun S, Wang Z. Head neck squamous cell carcinoma c-Met+ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer 2011;129:2337-48.
42. Li H, Gao Q, Guo L, Lu SH. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 2011;11:950-8.
43. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 2007;104:16158-63.
44. Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, et al. Singlemarker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010;32:1195-201.
45. Warrier S, Bhuvanalakshmi G, Arfuso F, Rajan G, Millward M, Dharmarajan A. Cancer stem-like cells from head and neck cancers are chemosensitized by the Wnt antagonist, sFRP4, by inducing apoptosis, decreasing stemness, drug resistance and epithelial to mesenchymal transition. Cancer Gene Ther 2014;21:381-8.
46. Bertrand G, Maalouf M, Boivin A, Battiston-Montagne P, Beuve M, Levy A, et al. Targeting head and neck cancer stem cells to overcome resistance to photon and carbon ion radiation. Stem Cell Rev 2014;10:114-26.